Overview

Investors shared how they judge “pilot-to-scale” in healthcare: tackle a truly painful problem, prove hard-dollar ROI, map stakeholders, under-promise/over-deliver, and design pilots that mirror real production (not one-off department wins). They stressed how healthcare AI differs—heavy regulation, tiny buyer universe, deep domain know-how required—and why trust is paramount since products touch patients. Looking ahead to 2030, themes were AI that eases the caregiver shortfall (aging populations), continuous diagnosis/intervention from richer data, and pragmatic wins like cheap digital pathology—where venture’s job is long-horizon, high-integrity company building.